SOURCE: Solos Endoscopy, Inc.

March 17, 2016 11:42 ET

Solos Endoscopy Fulfills Backorders for MammoView® Ductoscopy Instruments

BOSTON, MA--(Marketwired - Mar 17, 2016) - Solos Endoscopy, Inc. (OTC PINK: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the company has resumed sales of its MammoView® Ductoscopy Instruments as a result of its ability to fulfill all of its backorders, which were due to production issues experienced from one of its component manufacturers. The component manufacturer has resolved its production issue and has resumed its deliveries, on a timely basis, to Solos and is confident that it will not experience this issue in the future.

"The production issues have been successfully addressed and I'm confident in the uninterrupted sale and production of the MammoView® product line going forward," stated Robert Segersten, CEO.

Mammary ductoscopy is designed to provide physicians the means to detect, diagnose, and treat breast cancer years before surgery, physical exams or other external imaging, which can reveal evidence of the disease. The Solos Breast Endoscopy System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of the breast cancers arise. Solos' intraductal devices are designed to provide direct observation with any endoscopic video system while providing unprecedented image quality, using advanced minimally invasive technologies and tissue preservation techniques.

Solos Endoscopy instruments are FDA approved. The FDA approval also covers the entire MammoView® instrument line. The Company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.

Solos Endoscopy recently completed a capital restructuring initiative in order to position itself for growth over the next twelve months. The Company plans to raise capital in order to fulfill outstanding purchase orders and pursue sales initiatives overseas.

About Solos Endoscopy, Inc.

Solos Endoscopy recently celebrated its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact Information

  • Solos Endoscopy, Inc.
    Investor Relations
    (617) 360-9719